/PRNewswire/ The Special Committee of Independent Directors of MDC Partners Inc. (NASDAQ: MDCA) ("MDC Partners" or the "Company") responded today to press.
Article content
Total voting support agreements for the Transaction now represent 44.4%, or 162.7 million, of the total votes outstanding including all senior management and board members
Shareholders to benefit from a global platform of premium and super premium brands and distribution through Canada, Israel and Europe
The Transaction has been approved by an MYM Special Committee of Independent Directors
We apologize, but this video has failed to load.
Try refreshing your browser.
Vancouver, British Columbia–(Newsfile Corp. – April 19, 2021) – MYM Nutraceuticals Inc. (CSE: MYM) (OTCQB: MYMMF)
(“MYM” or the “Company”), is pleased to announce that it has received additional voting support agreements in connection with the proposed merger with IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (“
Solara Active Pharma and Aurore Life Sciences Limited combine to create second largest Pure Play API / CRAMs company in India equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Canoo Names Claudia Romo Edelman and Arthur Kingsbury to Board
Appointments reinforce Canoo s commitment to building a high-growth company and world-class brand
News provided by
Share this article
LOS ANGELES, March 15, 2021 /PRNewswire/
Canoo Inc. (Nasdaq: GOEV), a company developing breakthrough purpose built electric vehicles (EVs) with a proprietary and highly versatile platform architecture, has named Claudia Romo Edelman and Arthur Kingsbury to the Board of Directors, effective immediately. Based on my years of experience building high-growth companies, I wanted to assemble a board with diverse skills to build Canoo into a global leader and deliver our customer-focused value proposition, said Tony Aquila, Executive Chairman of Canoo. Our board members have extensive experience in innovation, technology, automotive as well as environmental, social & corporate governance and their insights will help guide the growth of our company. Art has deep expertise in bus
Strides Board approves demerger of its Biotech business under Stelis Biopharma
Bengaluru, Feb 4 (UNI) Strides Pharma Science Limited (Strides), Bengaluru headquartered global Pharmaceutical Company on Thursday announced that its Board of Directors have approved in principle the demerger of its biotech business under Stelis Biopharma (Stelis).
The demerger is expected to unlock significant value for Strides shareholders.
A Committee will be formed to explore various options of value discovery including listing of the business on a standalone basis and recommend to the Audit Committee, Committee of Independent Directors and Board including the Scheme, swap ratio and way forward, according to a release here on Thursday.